期刊文献+

采用集合RNA检测方法估计高危人群的HIV感染发病率 被引量:3

Estimation on the HIV-1 incidence among high risk groups using the pooling RNA technique
原文传递
导出
摘要 目的及时发现艾滋病自愿咨询检测(VCT)人群和男男性行为人群(MsM)HIV抗体窗口期感染者,并估计发病率。方法收集2012年1—10月云南省疾病预防控制中心VCT门诊和MSM活动室H1V抗体筛查阴性样本,以50:1和10:1二级集合方式进行HIV-1RNA检测,并随访HIV-1RNA阳性者,最后以RonBrookmeyer方法估计VCT和MSM人群的HIV感染年发病率。结果1400份VCT门诊HIV抗体筛查阴性样本中,发现2名HIV-1RNA阳性窗口期感染者,HIV感染年发病率为1.87%(95%CI:1.23%~2.65%)。MSM500份HIV抗体筛查阴性样本中,发现2名HIV-1RNA阳性窗口期感染者,HIV感染年发病率为5_31%(95%CI:3.52%~7.45%)。结论集合RNA检测为及时发现VCT和MSM的HIV窗口期感染者提供有效方法,建议通过提高集合RNA检测频率等方式,加强MSM及其他高危人群HIV感染窗口期的筛查。 Objective To timely identify the HIV-1 infection in window-period and to estimate the HIV-1 incidence among people who came for voluntary counseling and testing (VCT) service as well as men who have sex with men(MSM) ,respectively. Methods HIV antibody negative samples that were determined by screening tests between January and October 2012, were collected and tested with pooling HIV-1 RNA testing technique (2-staged pooling by 50 : 1,10 : 1 ). Positive cases were followed-up for HIV antibody testing while HIV incidence was calculated under Ron Brookmeyer' s method, among VCT and MSM populations. Results Among 1400 HIV antibody negative samples of VCT, two showed HIV-1 RNA positive during the antibody window period with the HIV-I incidence as 1.87% per year (95% CI: 1.25%-2.65% ). Among 500 HIV antibody negative samples from MSM population, two showed HIV-1 RNA positive in the antibody window period, with HIV-1 incidence as 5.31% per year (95% Ch 3.52%-7.45% ). Conclusion Pooling HIV-1 RNA testing seemed a powerful tool for HIV antibody testing in the window-period. Measures should be taken to strengthen the HIV diagnostic programs among MSM and other high risk groups, during the HIV antibody window-period. More frequent detection approach as pooling HIV-1 RNA testing might be a good choice.
出处 《中华流行病学杂志》 CAS CSCD 北大核心 2013年第8期812-814,共3页 Chinese Journal of Epidemiology
基金 基金项目:国家“十二五”科技重大专项(2012ZX10001-006)
关键词 艾滋病病毒 集合RNA检测 窗口期 高危人群 Human immunodeficiency virus Pooling RNA testing Window period High risk groups
  • 相关文献

参考文献8

  • 1Miller WC, Rosenberg NE, Rutstein SE, et al. The role of acute and early HIV infection in the sexual transmission of HIV. Curt Opin HIV AIDS, 2010,5 (4) : 277-282.
  • 2中国疾病预防控制中心.全国艾滋病检测技术规范(2009年修订版).,2009..
  • 3Brookmeyer R. The analysis of multistage pooling studies of biological specimens for estimating disease incidence and prevalence. Biometrics, 1999,55 (2) : 608-612.
  • 4刘关键,洪旗.可信区间的用途和意义[J].中国循证医学,2001,1(4):235-238. 被引量:4
  • 5Busch MP, Lee LL, Satten GA, et al. Time course of detection of viral and serologic markers preceding human immunodeficiency virus type 1 seroconversion: implications for screening of blood and tissue donors. Transfusion, 1995,35 (2) : 91-97.
  • 6Daar ES, Little S, Pitt J, et al. Diagnosis of primary HIV-1 infection. Ann Intern Med, 2001,134( 1 ) : 25-29.
  • 7Hart XX, Xu J J, Chu ZX, et al. Screening acute HIV infections among Chinese men who have sex with men from voluntary counseling & testing centers. PLoS One, 2011,6 (12) : e29792.
  • 8Lau JTF, Lin C, Hao C, et al. Public health challenges of the emerging HIV epidemic among men who have sex with men in China. Public Health, 2011,125 : 260-265.

二级参考文献3

  • 1王家良.临床流行病学[M](第2版)[M].上海:上海科学技术出版社,2001.57.
  • 2杨树勤.卫生统计学[M].第3版.北京:人民卫生出版社,1996.55-63.
  • 3David L, Sackett, W.Scott Richardson, William Rosenberg, et al, Evidence-based medicine-how to practice and teach EBM. [M] The second edition.Churchill Livingstone Publish House. Toronto:2000.

共引文献6

同被引文献60

  • 1中华人民共和国卫生部,联合国艾滋病规划署,世界卫生组织.2011年中国艾滋病疫情估计报告[R].北京:中华人民共和国卫生部,联合国艾滋病规划署,世界卫生组织,2011.
  • 2NME Drug and New Biologic Approvals in 2007 [ EB/OL]. http: //www. fda. gov /drugs/ developmentapprovalprocess/howdrugsaredevelo-pedandapproved/drugandbiologicapprovalreports/ucmO^>l69Q. htm,2009-02-10/ 2014-05-20.
  • 3Isentress( raltegravir) indication extended for the treatment of HIV-1infection in treatment-naive patients [ EB/OL ]. http: // www. fda.gov/forconsumers/byaudience/forpatientadvocates/ hivandaidsactivi-ties/ucm\imi. to,2009-07-13/ 2014-05-20.
  • 4Isentress ( raltegravir) : pediatric dosing recommendations and 2chewable tablet formulations for pediatric dosing[ EB/OL] . http: //www. fda, gov/forconsumers /byaudience/forpatientadvocates/ hivan-daidsactivities/ucm2S4592. htm, 2011-12-21/2014-05-20.
  • 5Summa V,Petrocchi A,Bonelli F,et al. Discovery of raltegravir,a po-tent ,selective orally bioavailable HIV-integrase inhibitor for the treat-ment of HIV-AIDS infection [ J ]. J Med Chem, 2008,51 (18) :5843-5855.
  • 6Iwamoto M,Wenning LA,Petry AS,et al. Safety,tolerability and phar-macokinetics of raltegravir after single and multiple does in healthysubjects[ J]. Clin Pharmacol Ther,2008 ,83(2) :293-299.
  • 7Blanco JL,Vairghese V,Rhee SY, et al. HIV-1 integrase inhibitor re-sistance and its clinical implications[ J] ? J Infect /)^,2011,203(9):1204-1214.
  • 8Kassahun M,Macintosh I,Cui D, et al. Metabolism and diposition inhumans of raltegravir ( MK-0518 ),an anti-AIDS drug targeting thehuman immunodeficiency virus 1 integrase enzyme [ J]. Drug MetabDispos,2007,35(9) : 1657-1663.
  • 9Rochstroh JK, Dejesus E, Lennox JL. Durable efficacy and safety ofraltegravir versus efavirenz when combined with tenofovir/emtricit-abine in treatment-naive HIV-1-infected patients : final 5 -year resultsfrom STARTMRK [ J] . / Acquir Immune Defic Syndr,2013 ,63 ( 1 ):.77-85.
  • 10Gotuzzo E,Markowitz M,Ratanasuwan W. Sustained efficacy and safe-ty of raltegravir after 5 years of combination antiretroviral therapy asinitial treatment of HIV-1 infection : final results of a randomized,con-trolled ,phase fl study[ J]. J Acquir Immune Defic Syndr, 2012,61(1) :73-77.

引证文献3

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部